Straight to content

Make future corona medicine affordable and accessible for everyone

Posted in category:
Statement
Published on:

Since the outbreak of the new coronavirus, the European Commission has allocated millions of Euros to promote research on COVID-19. Several national governments have also mobilised substantial resources to support the development of diagnostics, treatments and vaccines.

In this letter, a broad coalition of ngos, including SOMO, urge the EU institutions and national governments not to allow ‘business as usual’ approach in which market dynamics dictate price setting at the expense of rapid access, and where financial considerations – rather than public health – guide where and when products will be available.

They strongly recommend that the EU institutions and national governments incorporate collective, pro-public safeguards, in current and future funding calls and investments, such as:

Do you need more information?

Download

Posted in category:
Statement
Published on:

Related news

Don't want to miss anything?

Sign up for our newsletter and always stay up to date on information and analysis on corporate power issues.